Can-Fite’s results on the inhibition of liver cancer by cannabis compounds are published in HEPATOLOGY and will be presented at AASLD’s The Liver Meeting® 2021 conference
The cannabis fraction rich in CBD T3 / C15 acts via the A3AR target to inhibit the growth of hepatocellular carcinoma HEP-3b cells
PETACH TIKVA, Israel, November 01, 2021– (BUSINESS WIRE) – Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that treat inflammatory, cancer and liver diseases, today announced the CEO, Dr. Pnina Fishman, will make a poster presentation titled “Growth Inhibition of Hepatocellular Carcinoma (HCC) by CBD Rich T3 / C15 Cannabis Fraction is Mediated via the A3 Adenosine Receptor” at the American Association for the Study of Liver Diseases (AASLD). Liver MeetingÂ® in hepatobiliary neoplasia: experimental hepatocarcinogenesis; Liver diagnostic and imaging session. The poster will be available for consultation by participants throughout the meeting. The results were published in a summary in the October 2021 supplement of Hepatology, a leading peer-reviewed publication in the field of liver disease published on behalf of AASLD.
The Liver Meeting, which takes place virtually November 12-15, 2021, brings together clinicians, associates and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts. in the field of hepatology.
Can-Fite is a world leader in the discovery and development of drugs targeting the A3 adenosine receptor (A3AR). In preclinical studies, Can-Fite showed that a CBD-rich cannabis fraction T3 / C15 inhibited the growth of hepatocellular carcinoma HEP-3b cells in the liver via A3AR by inhibiting regulatory pathways related to Wnt and NF- kappa B. The Company has filed patent applications protecting its discovery of cannabinoid-based therapies in which the A3AR target is overexpressed, including liver cancer.
About Can-Fite BioPharma Ltd.
This press release may contain forward-looking statements regarding Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, its activities, its financial condition, its results. operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, either orally or in writing. Forward-looking statements may be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should” or “anticipate” or their negatives or other variations of these or other comparable words or in that such statements do not relate strictly to historical or current matters. These forward-looking statements may be included, without limitation, in various documents filed by Can-Fite with the United States Securities and Exchange Commission, press releases or oral statements made by or with the approval of the one of Can-Fite’s authorized officers. officers. Forward-looking statements relate to events, activities, trends or results anticipated or expected on the date they are made. Because forward-looking statements relate to matters which have not yet occurred, such statements are inherently subject to risks and uncertainties which could cause Can-Fite’s actual results to differ materially from any future results. expressed or implied by forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in these forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in these forward-looking statements include, but are not limited to: our history of losses and our need for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or not at all; uncertainties in cash flow and inability to meet working capital requirements; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; implementing our business model and strategic plans for our business and product candidates; the extent of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to conduct our business without infringing the intellectual property rights of others; competitive businesses, technologies and our industry; statements on the impact of the political and security situation in Israel on our activities; and the risks and other risk factors detailed in documents filed by Can-Fite with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industrial sector where securities values ââare highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite assumes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211101005023/en/